EGFR-mutated NSCLC: A roadmap to treatment sequences

Med. 2024 Sep 13;5(9):1044-1047. doi: 10.1016/j.medj.2024.07.010.

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for the management of EGFR-mutated non-small cell lung cancer. Recent results from the HARMONi-A trial lead to considering ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF-plus chemotherapy as a new second-line option following third-generation TKIs.

MeSH terms

  • Antibodies, Bispecific / pharmacology
  • Antibodies, Bispecific / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors* / antagonists & inhibitors
  • ErbB Receptors* / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Tyrosine Kinase Inhibitors* / pharmacology
  • Tyrosine Kinase Inhibitors* / therapeutic use

Substances

  • Antibodies, Bispecific
  • EGFR protein, human
  • ErbB Receptors
  • Tyrosine Kinase Inhibitors